Aurora Capital LLC is a boutique investment bank and securities firm founded in 1994. Investment banking is comprised of an experienced team of professionals specializing in the life science sector, which utilizes a rigorous process in the selection of investment ideas and investment banking clients.
As of March 22, 2013, affiliates of Aurora Capital were elected to a majority of the positions at Cortex Pharmaceuticals, Inc. (CORX). For more information, view recent filings and news.
In addition to in-house expertise and experienced personnel, Aurora retains the services of a network of qualified scientific, medical, and other advisors. Aurora's enduring objective is attempting to achieve equitable valuations for our investment banking clients while concurrently providing investor returns commensurate with the risks inherent in emerging technologies. On the securities and brokerage side of the business, we are teams of knowledgeable and experienced registered representatives with depth of understanding and broad capabilities to meet the challenges of our customers' investing needs and who also have unique access to the securities offerings of the investment banking department, the resources of our clearing firm and the broad understanding of the life science sector of the firm as a whole. Click to view our Track Record and Tombstone.
Our Hedge Fund/Direct Participation Program Group raises capital for hedge funds, funds of funds and direct participation programs. It offers these unique investment opportunities only to select groups of highly qualified institutions, individuals and related entities.
Aurora is based in New York City, with offices in Rockland County, New York, San Francisco, California and Boca Raton, Florida. We are dedicated to serving life science companies and their investors as well as our customers’ general investing needs. We seek to: (i) provide valuable or undiscovered investment opportunities to our investing clients and (ii) provide high quality service to a corporate finance client base which may be overlooked or underserved by the major and regional investment banking organizations primarily due to company or transaction size.
As of March 22, 2013, affiliates of Aurora Capital were elected to a majority of Board of Director and Executive Team positions at Cortex Pharmaceuticals, Inc. (CORX). For more information, view recent filings and news.
Recent SEC Filings Related to Cortex:
Form 3 Filings: 4/1/2013 Initial Statement of Beneficial Ownership of Securities
Form_8K_Filing: 3/22/2013 Cortex Pharmaceuticals, Inc. - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Form_8K_Filing: 3/22/2013 Termination of licensing agreement between Univeristy of Illinois and Pier Pharmaceuticals, Inc., a wholly-owned subsidiary of Cortex Pharmaceuticals, Inc. (CORX)
Schedule_13D_Filing: 3/21/2013 Aurora affiliates acquire beneficial ownership of publicly traded securities in Cortex Pharmaceuticals, Inc. (CORX)